156 related articles for article (PubMed ID: 9454655)
1. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
[TBL] [Abstract][Full Text] [Related]
2. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
Cormio G; Di Vagno G; Melilli GA; Cazzolla A; Di Gesù G; Carriero C; Cramarossa D; Loverro G; Selvaggi L
J Chemother; 1999 Oct; 11(5):407-9. PubMed ID: 10632389
[TBL] [Abstract][Full Text] [Related]
4. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
5. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
[TBL] [Abstract][Full Text] [Related]
6. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
[TBL] [Abstract][Full Text] [Related]
8. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
9. [Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
Lehoczky O; Bagaméri A; Pulay T
Orv Hetil; 2002 Sep; 143(38):2189-91. PubMed ID: 12395475
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
11. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
12. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
13. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
14. Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.
Frigerio L; Mangili G; Aletti G; Carnelli M; Garavaglia E; Beatrice S; Ferrari A
Gynecol Oncol; 2001 Apr; 81(1):53-7. PubMed ID: 11277649
[TBL] [Abstract][Full Text] [Related]
15. Eosinophilic ascites: taxol-induced hypersensitivity?
Kobayashi TK; Muramatsu M; Ueda M; Nishino T; Bamba M; Urabe M; Moritani S
Cytopathology; 2004 Jun; 15(3):171-2. PubMed ID: 15165278
[No Abstract] [Full Text] [Related]
16. One-hour paclitaxel infusions: review of safety and efficacy.
Greco FA; Thomas M; Hainsworth JD
Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
18. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Yamazaki S; Sekine I; Saijo N
Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
[TBL] [Abstract][Full Text] [Related]
20. [A case successfully treated by desensitization for paclitaxel-associated hypersensitivity reactions].
Yamatoya Y; Wada Y; Sato S; Morikawa T; Sakata N; Nakata J; Seki K; Wada N; Kamiyama K; Tominaga T
Gan To Kagaku Ryoho; 2007 Feb; 34(2):271-4. PubMed ID: 17301542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
